我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

多花黄精多糖对STZ诱导的Ⅰ型糖尿病小鼠影响作用研究*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2019年01期
页码:
1-7
栏目:
实验研究
出版日期:
2019-10-29

文章信息/Info

Title:
Hypoglycemic Effects of Polysaccharide of Polygonatum Cyrtonema Hua on Type1 Diabetic Mice Induced by STZ
文章编号:
1000-2723(2019)01-0001-07
作者:
王秋丽1童小慧2李小东1韩荣春1彭代银1俞年军1△
(1. 安徽中医药大学 安徽省中医药科学院 中药资源保护与开发研究所,安徽 合肥 231200;2. 安徽中医药大学中西医结合学院,安徽 合肥 230012)
Author(s):
WANG Qiuli1 TONG Xiaohui2 LI Xiaodong1 HAN Rongchun1 PENG Daiyin1 YU Nianjun1
(1. Institute of Resource Protection and Development of Traditional Chinese Medicine, Anhui Academy of Traditional Chinese Medicine, Anhui University of Chinese Medicine, Hefei 231200, China;2. College of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei 230012, China)
关键词:
多花黄精多糖 Ⅰ型糖尿病 存活率 肝保护
Keywords:
polysaccharide of P.cyrtonema Hua typeⅠdiabetes survival rates liver protection
分类号:
R285.5
DOI:
10.19288/j.cnki.issn.1000-2723.2019.01.001
文献标识码:
A
摘要:
目的研究多花黄精多糖对Ⅰ型糖尿病小鼠血糖、存活率及肝保护等的影响。方法采用连续腹腔注射链脲佐菌素(STZ),建立雌性C57BL/6c小鼠Ⅰ型糖尿病模型。实验分四组:空白对照组、模型组、多花黄精多糖低剂量组(450 zmg·kg-1)和高剂量组(900 mg·kg-1)。实验中检测各组小鼠存活率、体重以及血糖变化。实验结束后,分离小鼠肝脏,采用HE染色法评价肝脏病理变化,实时定量PCR(qPCR)法检测肝脏中白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)、胰岛素受体底物1(IRS-1)mRNA水平。结果雌性C57BL/6c小鼠连续5天腹腔注射STZ,一周后可使血糖明显升高。在高血糖状态下,模型组小鼠死亡率急剧上升,多花黄精多糖高剂量显著提高模型小鼠的存活率;多花黄精多糖低、高剂量可显著增加模型小鼠体重;同时,多花黄精多糖高剂量有一定程度降低血糖的作用。HE染色结果显示,模型小鼠肝脏病变明显:出现大量的单核炎症细胞浸润,肝细胞发生变性明显。并且,肝细胞结构紊乱。而多花黄精多糖高剂量能够改善模型小鼠肝脏炎症浸润、肝细胞变性以及肝脏结构紊乱等病变。qPCR结果显示多花黄精多糖能显著降低糖尿病肝脏中IL-6,IL-1β mRNA的水平,显著升高IRS-1 mRNA的水平。结论多花黄精多糖显著降低Ⅰ型糖尿病小鼠的死亡率,可能与其改善小鼠体重、降低血糖、肝保护等相关。
Abstract:
Objective This experiment is intended to explore effects of polysaccharide of P.cyrtonema Hua on glycemia, survival rates and liver protection in streptozotocin(STZ) induced Ⅰ diabetes mice. Methods Type I diabetes was induced in female C57BL/6c mice by continuous intraperitoneal injection of STZ(70 mg·kg-1). Mice was randomly divided into four groups:control, model, polysaccharide of P.cyrtonema Hua of low-dose(450 mg·kg-1) and high group(900 mg·kg-1). One week after the first injection of STZ, mice in each group were given corresponding drugs by gavage, with mice in control and model group dosaged with water. The survival rate, body weight and blood glucose of mice were measured. at the end of the experiment, liver was isolated and the histological changes were evaluated by HE staining. Gene expressions of IL-6, IL-1β, IRS-1 in the liver were detected by qPCR. Results Female C57BL/6c mice’s blood glucose rapidly increased one week after being injected with STZ(70 mg·kg-1) for 5 consecutive days. Hyperglycemia sharply increased the mortality of mice, which was significantly reversed by high dose of polysaccharide of P.cyrtonema Hua. Besides, low and high dose of polysaccharide of P.cyrtonema Hua(450-900 mg·kg-1) significantly increased the body weight of model mice to some extent. Polysaccharide of P.cyrtonema Hua slightly but significantly reversed hyperglycemia in model mice. Histologically, liver damage of model mice was demonstrated with mononuclear inflammatory cells infiltration, hepatocyte cytoplasm and nuclear pyknosis. High dose of polysaccharide of P.cyrtonema Hua can ameliorate these pathological changes such as inflammation, liver cell degeneration and liver structural loss of model mice. qPCR results confirmed that, compared with the model group, polysaccharide of P.cyrtonema Hua could significantly reduce the levels of IL-6 and IL-1 beta mRNA and increase the levels of IRS-1 mRNA in the liver. Conclusion Polysaccharide of P.cyrtonema Hua significantly reduced the acute mortality of T1DM mice, which may be accounted by increase in body weight, blood glucose drop as well as hepatic protection.

参考文献/References

[1] BAIG N A, HERRINE S K, RUBIN R. Liver disease and diabetes mellitus[J]. Clin Lab Med,2001,21(1):193-207.
[2] 罗 敏,章文伟,邓才富,等. 药用植物多花黄精研究进展[J]. 时珍国医国药,2016,27(6):1467-1469.
[3] 国家药典委员会. 中华人民共和国药典:一部[S]. 北京:中国科技医药出版社,2015:306.
[4] 赵宏丽,许 燕,赵红岩,等. 黄精多糖对2型糖尿病大鼠SREBP-1c和SCD-1蛋白表达的影响[J]. 中药药理与临床,2015,31(1):106-109.
[5] 李友元,邓洪波,向大雄,等. 黄精多糖的降血脂及抗动脉粥样硬化作用[J]. 中国动脉硬化杂志,2005,13(4):429-431.
[6] 李友元,邓洪波,张 萍,等. 黄精多糖对糖尿病模型小鼠糖代谢的影响[J]. 中国临床康复,2005,9(27):90-91.
[7] XU D, KONG T, MA J. The inhibitory effect of extracts from Fructus lycii and Rhizoma polygonation in vitro DNA breakage by alternariol[J]. Biomed Environ Sci,1996,9(1):67-70.
[8] 叶红翠,张小平,余 红,等. 多花黄精粗多糖抗肿瘤活性研究[J]. 中国实验方剂学杂志,2008,14(6):34-36.
[9] WANG S, YU Q, BAO J, et al. Polygonatum cyrtonema lectin,a potential antineoplastic drug targeting programmed cell death pathways[J]. Biochem Biophys Res Commun,2011,406(4):497-500.
[10] 郑春艳. 九华山多花黄精皂甙和多糖的分离与纯化[D]. 芜湖:安徽师范大学,2010.
[11] 郑春艳,汪好芬,张庭廷. 黄精多糖的抑菌和抗炎作用研究[J]. 安徽师范大学学报(自然科学版),2010,33(3):272-275.
[12] LIU X, WAN Z, SHI L, et al. Preparation and antiherpetic activities of chemically modified polysaccharides from Polygonatum cyrtonema Hua[J]. Carbohydr Polym,2011,83(2):737-742.
[13] 刘静. 黄精“轻身”机制探讨[D]. 广州:广州中医药大学,2013.
[14] SCHNEDL W J, FERBER S, JOHNSON J H, et al. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells[J]. Diabetes,1994,43(11):1326-1333.
[15] 白俊毅,沈 立,张艳琳,等. 复方中黄精多糖的提取纯化工艺研究[J]. 现代中药研究与实践,2010,24(3):52-55.
[16] CRUZ B, FLORES R J, URIBE K P, et al. Insulin modulates the strong reinforcing effects of nicotine and changes in insulin biomarkers in a rodent model of diabetes[J]. Neuropsychopharmacology,2019,44(6):1141-1151.
[17] DANAEI G, FINUCANE M M, LU Y, et al. National,regional,and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants[J]. Lancet,2011,378(9785):31-40.
[18] LUKIC M L, PEJNOVIC N, LUKIC A. New insight into early events in type 1 diabetes:role for islet stem cell exosomes[J]. Diabetes,2014,63(3):835-837.
[19] DELANEY M F, ZISMAN A, KETTYLE W M. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome[J]. Endocrinol Metab Clin North Am,2000,29(4):683-705.
[20] EL-HELOU V, PROULX C, BEGUIN P, et al. The cardiac neural stem cell phenotype is compromised in streptozotocin-induced diabetic cardiomyopathy[J]. J Cell Physiol,2009,220(2):440-449.
[21] NORGAARD S A, SAND F W, SORENSEN D B, et al. Softened food reduces weight loss in the streptozotocin-induced male mouse model of diabetic nephropathy[J]. Lab Anim,2018,52(4):373-383.
[22] CHANDRAMOULI C, REICHELT M E, CURL C L, et al. Diastolic dysfunction is more apparent in STZ-induced diabetic female mice,despite less pronounced hyperglycemia[J]. Sci Rep,2018,8(1):2346.
[23] KANNEL W B, MCGEE D L. Diabetes and cardiovascular disease. The Framingham study[J]. JAMA The Journal of the American Medical Association,1979,241(19):2035-2038.
[24] CHAUDHARI H N, KIM S W, YUN J W. Gender-dimorphic regulation of DJ1 and its interactions with metabolic proteins in streptozotocin-induced diabetic rats[J]. J Cell Mol Med,2015,19(5):996-1009.
[25] PANENI F, BECKMAN J A, CREAGER M A, et al. Diabetes and vascular disease:pathophysiology,clinical consequences,and medical therapy:part I[J]. Eur Heart J,2013,34(31):2436-2443.
[26] WELSH J A, KARPEN S, VOS M B. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents,1988-1994 to 2007-2010[J]. J Pediatr,2013,162(3):496-500.
[27] HAIDARA M A, DALLAK M, ELKARIB A O, et al. Insulin protects against hepatocyte ultrastructural damage induced by type 1 diabetes mellitus in rats[J]. Ultrastruct Pathol,2018,42(6):508-515.
[28] GAO B, JEONG W I, TIAN Z. Liver:An organ with predominant innate immunity[J]. Hepatology,2008,47(2):729-736.
[29] YI H S, JEONG W I. Interaction of hepatic stellate cells with diverse types of immune cells:foe or friend?[J]. Journal of gastroenterology and hepatology,2013,28(Suppl.1):99-104.
[30] NAGAREDDY P R, MURPHY A J, STIRZAKER R A, et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis[J]. Cell Metab,2013,17(5):695-708.
[31] LEE Y S, EUN H S, KIM S Y, et al. Hepatic immunophenotyping for streptozotocin-induced hyperglycemia in mice[J]. Sci Rep,2016(6):30656.

备注/Memo

备注/Memo:
收稿日期: 2019 - 01- 05
* 基金项目: 国家重点研发计划(2017YFC1701602);安徽省重点研究与开发计划项(1804b06020356);安徽中医药大学自 然重点项目(2019zrzd02)
第一作者简介: 王秋丽(1995-),女,在读硕士研究生,研究方向:中药质量评价与药效学研究。
△通信作者: 俞年军,E-mail:ynj2005288@sina.com
更新日期/Last Update: 2019-10-22